Unicycive Therapeutics, Inc. - Common Stock (UNCY)

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026. Unicycive describes itself as a “clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases.”

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options

A securities class action alleges Unicycive Therapeutics assured the market that its third-party manufacturer had made "significant progress" toward FDA compliance without ever inspecting the facility, and UNCY shares lost 39.1% of their value in a single session when a second Complete Response Letter was announced

A securities class action alleges Unicycive Therapeutics told investors its third-party manufacturer had made "significant progress" toward regaining FDA compliance, while the Company had never verified that claim through its own inspection of the facility

San Diego, California--(Newsfile Corp. - October 26, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.

NEW YORK CITY, NY / ACCESS Newswire / October 23, 2026 / Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) that a class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. See if you could be eligible to recover. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Unicycive Therapeutics, Inc. (Nasdaq: UNCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options

A securities class action alleges Unicycive Therapeutics told shareholders its oxylanthanum carbonate application was on track without ever inspecting its third-party manufacturer's facility for cGMP compliance. UNCY purchasers who lost $3.01 per share have specific rights under the federal securities laws.

A securities class action alleges Unicycive Therapeutics leaned on a contract manufacturer already cited by the FDA for cGMP deficiencies, without verifying the vendor's compliance status, before the same deficiencies triggered a second Complete Response Letter and a 39.1% single-day collapse in UNCY shares.

NEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) that a securities class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Submit your information. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

A securities class action contends Unicycive Therapeutics promised shareholders an FDA decision on June 29, 2026 and a commercial launch of oxylanthanum carbonate "later this year," while allegedly never inspecting the third-party manufacturing facility that had already triggered one Complete Response Letter.

A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Oct. 11, 2026 (GLOBE NEWSWIRE) --

NEW YORK CITY, NY / ACCESS Newswire / October 9, 2026 / Levi & Korsinsky, LLP alerts investors in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) that a securities class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) --

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options

San Diego, California--(Newsfile Corp. - October 5, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class...

NEW YORK CITY, NY / ACCESS Newswire / October 2, 2026 / Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) that a securities class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Submit your information now. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.